CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 38 enrolled
Drug / intervention
Insulin Lisprobiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02111083
NCT02111083Phase 1Completed

Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects

Eli Lilly and Company·interventional·Posted Apr 10, 2014·Updated May 21, 2015

In Brief

A Phase 1 clinical trial evaluating Insulin Lispro for Healthy Volunteers. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The study involves 4 injections of insulin lispro and its purpose is to: * Determine if 2 formulations of insulin lispro are treated by the body in a similar way. * Compare how the 2 formulations of insulin lispro affect blood sugar level. * Determine the safety of each insulin lispro formulations and any side effects that might be associated with them when given to healthy participants. The study is expected to last up to approximately 9 weeks for each participant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 10, 2014
Enrollment StartMay 1, 2014
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.2 years ago

Interventions

Insulin Lisprobiological

LY275585 administered SC.